CA2247009A1 - Cryptic peptides and method for their identification - Google Patents

Cryptic peptides and method for their identification

Info

Publication number
CA2247009A1
CA2247009A1 CA002247009A CA2247009A CA2247009A1 CA 2247009 A1 CA2247009 A1 CA 2247009A1 CA 002247009 A CA002247009 A CA 002247009A CA 2247009 A CA2247009 A CA 2247009A CA 2247009 A1 CA2247009 A1 CA 2247009A1
Authority
CA
Canada
Prior art keywords
peptide
cells
challenge
identification
challenged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002247009A
Other languages
French (fr)
Other versions
CA2247009C (en
Inventor
Anthony Barrington Kay
Mark Larche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circassia Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605904.3A external-priority patent/GB9605904D0/en
Priority claimed from GBGB9608430.6A external-priority patent/GB9608430D0/en
Application filed by Individual filed Critical Individual
Publication of CA2247009A1 publication Critical patent/CA2247009A1/en
Application granted granted Critical
Publication of CA2247009C publication Critical patent/CA2247009C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides a method of determining whether a peptide of a protein is a cryptic peptide, which method includes the steps of i) exposing T cells with the peptide in a primary challenge; ii) measuring the reactivity of T cells with the peptide in the primary challenge of step i); iii) exposing pre-challenged T cells with the peptide in a secondary challenge, wherein the pre-challenged T cells are obtainable by exposing the T cells to the protein; and measuring the reactivity of the pre-challenged T cells with the peptide in the secondary challenge of step iii), and the peptide is a cryptic peptide if T-cell reactivity is observable in the secondary challenge but not in the primary challenge.
CA002247009A 1996-03-21 1997-03-20 Cryptic peptides and method for their identification Expired - Lifetime CA2247009C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9605904.3A GB9605904D0 (en) 1996-03-21 1996-03-21 Peptides
GB9605904.3 1996-03-21
GB9608430.6 1996-04-24
GBGB9608430.6A GB9608430D0 (en) 1996-04-24 1996-04-24 Peptides
PCT/GB1997/000783 WO1997035193A1 (en) 1996-03-21 1997-03-20 Cryptic peptides and method for their identification

Publications (2)

Publication Number Publication Date
CA2247009A1 true CA2247009A1 (en) 1997-09-25
CA2247009C CA2247009C (en) 2009-08-04

Family

ID=26308965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247009A Expired - Lifetime CA2247009C (en) 1996-03-21 1997-03-20 Cryptic peptides and method for their identification

Country Status (11)

Country Link
US (1) US6737406B1 (en)
EP (2) EP0888541B1 (en)
JP (1) JP4340329B2 (en)
AT (2) ATE296444T1 (en)
AU (1) AU730198C (en)
CA (1) CA2247009C (en)
DE (2) DE69733343D1 (en)
DK (1) DK1612555T3 (en)
ES (1) ES2314515T3 (en)
GB (3) GB2352518B (en)
WO (1) WO1997035193A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812087B1 (en) 2000-07-21 2007-05-11 Inst Nat Sante Rech Med METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY
JPWO2002066979A1 (en) * 2001-02-22 2004-06-24 タカラバイオ株式会社 Method for detecting antigen causing bronchial asthma
PT1512004E (en) * 2002-06-11 2006-08-31 Merck Patent Gmbh METHOD FOR MAPPING AND ELIMINATING EPITHOPES FOR T-CELLS
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2286833A3 (en) * 2007-08-15 2011-09-14 Circassia Limited Peptides for desensibilization against allergens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633881B2 (en) 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー Immunomodulatory compositions and their use
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US6180368B1 (en) 1988-03-23 2001-01-30 University Of Melbourne Ryegrass pollen allergen
ATE175209T1 (en) 1989-03-17 1999-01-15 Immulogic Pharma Corp ALLERGIC PROTEINS FROM AMBROSIA AND USE THEREOF
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
DK0500785T3 (en) 1989-11-03 2002-08-19 Immulogic Pharma Corp Human T cell activity feline protein (TRFP) isolated from house dust as well as applications thereof
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
ES2133288T3 (en) 1990-09-11 1999-09-16 Inst Child Health Research CLONING AND SEQUENCING OF DERMATOPHAGOID ALLERGENS (HOUSEHOLD MITES).
CA2095323A1 (en) 1990-10-30 1992-05-01 Jonathan B. Rothbard Peptide binding assays with mhc antigens
WO1992011859A1 (en) 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite)
EP0595855A1 (en) 1991-07-12 1994-05-11 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
NZ299122A (en) 1991-10-16 2005-02-25 Immulogic Pharma Corp Detecting and treating allergies using peptides with T-cell stimulating activity
ATE444360T1 (en) 1991-10-16 2009-10-15 Merck Patent Gmbh T-CELL EPITOPES FROM THE MAIN ALLERGENS OF DERMATOPHAGOIDES (HOUSE MITES)
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
CA2117779A1 (en) 1992-04-09 1993-10-28 Mei-Chang Kuo T cell epitopes of the major allergens from ambrosia artemisifolia
WO1994003478A1 (en) 1992-07-31 1994-02-17 Immulogic Pharmaceutical Corporation Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen
WO1994011512A2 (en) 1992-11-12 1994-05-26 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
DK0677105T3 (en) 1992-12-31 2006-07-10 Immulogic Pharma Corp Allergy-causing proteins and peptides from dog bark and applications therefor
AU684501B2 (en) 1993-03-12 1997-12-18 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
NZ266739A (en) * 1993-06-02 1997-07-27 Tvw Telethon Inst Child Health Inducing immunologic tolerance by administering a cryptic peptide derived from the antigen der pi
NZ271818A (en) 1993-08-13 1997-11-24 Immulogic Pharma Corp T cell epitopes of ryegrass pollen antigen
AU2238395A (en) 1994-04-01 1995-10-23 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
ES2285703T3 (en) 1994-04-14 2007-11-16 Merck Patent Gmbh PHARMACEUTICAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF ALLERGY TO THE POWDER.
WO1996007428A1 (en) * 1994-09-02 1996-03-14 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
WO1996012737A2 (en) 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
AU4146796A (en) 1994-10-27 1996-05-23 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
AU4695296A (en) 1995-01-06 1996-07-24 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
WO1997032600A1 (en) 1996-03-10 1997-09-12 Meiji Milk Products Co., Ltd. Peptide-base immunotherapeutic agent for allergic diseases
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5

Also Published As

Publication number Publication date
GB0020260D0 (en) 2000-10-04
WO1997035193A1 (en) 1997-09-25
GB2352518B (en) 2001-04-04
AU730198C (en) 2002-03-14
GB0027373D0 (en) 2000-12-27
EP1612555A1 (en) 2006-01-04
JP2000508627A (en) 2000-07-11
DE69733343D1 (en) 2005-06-30
EP0888541B1 (en) 2005-05-25
US6737406B1 (en) 2004-05-18
ES2314515T3 (en) 2009-03-16
EP0888541A1 (en) 1999-01-07
GB2349463A (en) 2000-11-01
JP4340329B2 (en) 2009-10-07
DE69739062D1 (en) 2008-12-04
ATE412175T1 (en) 2008-11-15
CA2247009C (en) 2009-08-04
AU2036597A (en) 1997-10-10
DK1612555T3 (en) 2009-02-09
ATE296444T1 (en) 2005-06-15
GB9817461D0 (en) 1998-10-07
AU730198B2 (en) 2001-03-01
GB2326642A (en) 1998-12-30
GB2352518A (en) 2001-01-31
GB2349463B (en) 2001-01-10
GB2326642B (en) 2001-02-07
EP1612555B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
DK261386A (en) MONOCLONAL ANTIBODIES
DK0473961T3 (en) Immunoassay reagents and method for the determination of cyclosporin
CA2263129A1 (en) Mammalian cell surface antigens; related reagents
CA2054798A1 (en) Hcv-specific peptides, agents therefor and the use thereof
MY102885A (en) Method for determining mimotopes.
CA2255659A1 (en) Neuroactive peptides
AU4761493A (en) Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
DE69603656T2 (en) Gastight secondary cell
AU5320086A (en) Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
AU3460697A (en) Process for preparing hydrogen-containing gas for fuel cell
CA2247009A1 (en) Cryptic peptides and method for their identification
DE69617396D1 (en) Peptides affecting T cells
EP1652918A3 (en) Methods for detecting protein interactions using conformationally constrained peptides
AU3623197A (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
WO1998039421A3 (en) Mammalian proteinases; oxidoreductases; gtp binding proteins; related reagents
EP0253325A3 (en) Oncogene-related peptides
GB9816514D0 (en) Novel method
CA2100586A1 (en) Htlv-i and htlv-ii peptide antigens and methods
AU2284997A (en) Marker for male infertility and/or fertility
WO1997004311A3 (en) Cell sorting with fluorescent peptides
DE69534178D1 (en) S?ugetier thymokingene
WO1996040763A3 (en) Peptides for hiv-1 detection
EP0267622A3 (en) Method for detecting anti-adult t cell leukemia virus antibody
AU5171496A (en) Method of identifying clonal cell samples

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170320